Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial

IMPORTANCE: Approximately 25% of patients with early-stage breast cancer who receive (neo)adjuvant chemotherapy experience a recurrence within 5 years. Improvements in therapy are greatly needed. OBJECTIVE: To determine if pembrolizumab plus neoadjuvant chemotherapy (NACT) in early-stage breast canc...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :JAMA Oncol
Главные авторы: Nanda, Rita, Liu, Minetta C., Yau, Christina, Shatsky, Rebecca, Pusztai, Lajos, Wallace, Anne, Chien, A. Jo, Forero-Torres, Andres, Ellis, Erin, Han, Heather, Clark, Amy, Albain, Kathy, Boughey, Judy C., Jaskowiak, Nora T., Elias, Anthony, Isaacs, Claudine, Kemmer, Kathleen, Helsten, Teresa, Majure, Melanie, Stringer-Reasor, Erica, Parker, Catherine, Lee, Marie C., Haddad, Tufia, Cohen, Ronald N., Asare, Smita, Wilson, Amy, Hirst, Gillian L., Singhrao, Ruby, Steeg, Katherine, Asare, Adam, Matthews, Jeffrey B., Berry, Scott, Sanil, Ashish, Schwab, Richard, Symmans, W. Fraser, van ‘t Veer, Laura, Yee, Douglas, DeMichele, Angela, Hylton, Nola M., Melisko, Michelle, Perlmutter, Jane, Rugo, Hope S., Berry, Donald A., Esserman, Laura J.
Формат: Artigo
Язык:Inglês
Опубликовано: American Medical Association 2020
Предметы:
Original Investigation
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7058271/
https://ncbi.nlm.nih.gov/pubmed/32053137
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.6650
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы